News Image

Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.

By Mill Chart

Last update: Dec 6, 2023

Uncover the potential of SANOFI-ADR (NASDAQ:SNY) as our stock screener's choice for an undervalued stock. NASDAQ:SNY maintains a strong financial position and offers an appealing valuation. We'll delve into the specifics below.

Understanding NASDAQ:SNY's Valuation

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:SNY scores a 8 out of 10:

  • SNY is valuated reasonably with a Price/Earnings ratio of 10.12.
  • Based on the Price/Earnings ratio, SNY is valued cheaply inside the industry as 89.22% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 24.81. SNY is valued rather cheaply when compared to this.
  • SNY is valuated reasonably with a Price/Forward Earnings ratio of 9.60.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 88.73% of the companies listed in the same industry.
  • SNY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 19.91.
  • SNY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SNY is cheaper than 95.10% of the companies in the same industry.
  • SNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SNY is cheaper than 88.73% of the companies in the same industry.
  • The excellent profitability rating of SNY may justify a higher PE ratio.

Evaluating Profitability: NASDAQ:SNY

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:SNY has achieved a 8:

  • Looking at the Return On Assets, with a value of 10.12%, SNY belongs to the top of the industry, outperforming 93.14% of the companies in the same industry.
  • The Return On Equity of SNY (17.47%) is better than 91.18% of its industry peers.
  • SNY has a Return On Invested Capital of 15.53%. This is amongst the best in the industry. SNY outperforms 92.16% of its industry peers.
  • The 3 year average ROIC (6.95%) for SNY is below the current ROIC(15.53%), indicating increased profibility in the last year.
  • Looking at the Profit Margin, with a value of 18.09%, SNY belongs to the top of the industry, outperforming 93.14% of the companies in the same industry.
  • SNY has a better Operating Margin (27.75%) than 94.12% of its industry peers.
  • In the last couple of years the Operating Margin of SNY has grown nicely.
  • SNY has a better Gross Margin (70.31%) than 78.43% of its industry peers.

Deciphering NASDAQ:SNY's Health Rating

A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:SNY has received a 7 out of 10:

  • SNY has an Altman-Z score of 3.08. This indicates that SNY is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of SNY (3.08) is better than 76.47% of its industry peers.
  • The Debt to FCF ratio of SNY is 2.59, which is a good value as it means it would take SNY, 2.59 years of fcf income to pay off all of its debts.
  • SNY has a Debt to FCF ratio of 2.59. This is amongst the best in the industry. SNY outperforms 90.69% of its industry peers.
  • SNY has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
  • SNY does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.

ChartMill's Evaluation of Growth

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:SNY was assigned a score of 5 for growth:

  • The Earnings Per Share has grown by an nice 17.29% over the past year.
  • The Earnings Per Share has been growing by 8.29% on average over the past years. This is quite good.
  • SNY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.47%.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

Our latest full fundamental report of SNY contains the most current fundamental analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

SANOFI-ADR

NASDAQ:SNY (4/26/2024, 7:16:56 PM)

After market: 49.13 0 (0%)

49.13

-0.23 (-0.47%)

SNY News

News Image2 days ago - Swedish Orphan Biovitrum ABSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A

/PRNewswire/ -- Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion...

News Image3 days ago - The Motley FoolSanofi (SNY) Q1 2024 Earnings Call Transcript

SNY earnings call for the period ending March 31, 2024.

News Image3 days ago - InvestorPlaceSNY Stock Earnings: Sanofi Beats EPS, Beats Revenue for Q1 2024

SNY stock results show that Sanofi beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image3 days ago - Investor's Business DailyAstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags

AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

News Image17 days ago - InvestorPlaceThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

News Image20 days ago - InvestorPlaceWhy Is Auddia (AUUD) Stock Up 192% Today?

Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.

News Image20 days ago - InvestorPlaceAIRC Stock Alert: Blackstone Is Taking Apartment Income REIT Private

Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.

News Image20 days ago - InvestorPlaceSanofi Layoffs 2024: What to Know About the Latest SNY Job Cuts

Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.

SNY Links
Follow us for more